The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil ...

Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion ... Johnson's Erleada (apalutamide) and Pfizer/Astellas' Xtandi (enzalutamide ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data from select pipeline candidates across the Company's diversified oncology portfolio ...

Stocks of cancer treatment developers will be moving into the spotlight later this week when the annual meeting of the ...

During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...